Development of Proliferative Diabetic Retinopathy in African-Americans and Whites With Type 1 Diabetes

OBJECTIVE To investigate the comparable risk of developing proliferative diabetic retinopathy (PDR) in African-Americans and whites with type 1 diabetes. RESEARCH DESIGN AND METHODS Using a cohort design with the sample drawn from medical records, the sample consisted of 312 people with type 1 diabetes (97 African-Americans, 215 whites) having at least two visits to a Model Demonstration Unit with gradeable fundus photographs (stereo, color, 7 standard fields). Excluded were subjects with preexisting or treated PDR or hemoglobinopathy. Masked grading of the fundus photographs was conducted at the Wisconsin Reading Center. RESULTS At baseline, African-Americans had poorer glycemic control (mean HbA1 of 11.3 vs. 10.0%, P < 0.0001), higher systolic blood pressure (mean of 117 vs. 110 mmHg, P < 0.001), and were older (mean of 26.8 vs. 19.3 years, P < 0.0001) than the white subjects. African-Americans also tended to have slightly longer duration of diabetes and length of follow- up. In the African-Americans, 17.5% developed PDR, compared with 10.2% in the 215 whites, for an odds ratio (OR) of 1.86 (95% CI 0.93–3.70). When adjusted for baseline glycemic control, retinopathy grade, and length of follow-up, race was not a significant risk factor (OR = 0.73, 95% CI 0.30–1.78). CONCLUSIONS African-Americans with type 1 diabetes may have a higher rate of developing PDR. The observed racial difference, however, is attributable to the presence of a worse risk factor profile, especially to poorer glycemic control. Efforts should be expanded to improve the care for all individuals with poor glycemic control.

[1]  J. McGill,et al.  Retinopathy in African Americans and whites with insulin-dependent diabetes mellitus. , 1994, Archives of internal medicine.

[2]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[3]  D. Goldstein,et al.  Standardization of glycohemoglobin determinations in the clinical laboratory: three years of experience. , 1992, Clinical chemistry.

[4]  P. Savage,et al.  Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. , 1989, The New England journal of medicine.

[5]  D L DeMets,et al.  Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. , 1988, JAMA.

[6]  R. Klein,et al.  An alternative method of grading diabetic retinopathy. , 1986, Ophthalmology.

[7]  L. Rand,et al.  Risk of Proliferative Diabetic Retinopathy in Juvenile-Onset Type I Diabetes: A 40-yr Follow-up Study , 1986, Diabetes Care.

[8]  L. Melton,et al.  Risk Factors for Diabetic Retinopathy: A Population-Based Study in Rochester, Minnesota , 1986, Diabetes Care.

[9]  L. Rand,et al.  Multiple factors in the prediction of risk of proliferative diabetic retinopathy. , 1985, The New England journal of medicine.

[10]  D L DeMets,et al.  Prevalence of diabetes mellitus in southern Wisconsin. , 1984, American journal of epidemiology.

[11]  P Sinnock,et al.  The Epidemiology of Lower Extremity Amputations in Diabetic Individuals , 1983, Diabetes Care.

[12]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[13]  J. McDonald,et al.  Evaluation of three minicolumn procedures for measuring hemoglobin A1. , 1982, Clinical chemistry.

[14]  P. Bennett,et al.  Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. , 1980, The New England journal of medicine.